<DOC>
	<DOC>NCT01711840</DOC>
	<brief_summary>The purpose of the investigation is to confirm the safety of patients receiving Symbicort Turbuhaler as maintenance and reliever therapy ( Symbicort SMART) under the post-marketing actual use.</brief_summary>
	<brief_title>Clinical Experience Investigation of Symbicort Turbuhaler as Maintenance Therapy and Reliever Therapy</brief_title>
	<detailed_description>Symbicort Turbuhaler 30/60 Clinical Experience Investigation for treatment with Symbicort as maintenance therapy and as needed in response to symptoms</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Budesonide, Formoterol Fumarate Drug Combination</mesh_term>
	<criteria>Patients receiving Symbicort Turbuhaler as maintenance and reliever therapy for the first time due to 'bronchial asthma ',and possibly requiring asneeded inhalations during the observation period</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Bronchial asthma</keyword>
	<keyword>Symbicort Turbuhaler</keyword>
</DOC>